Bharat Biotech announced efficacy analysis data from Phase-3 clinical trials of Covaxin, proved to be highly effective against severe cases of COVID-19
The US FDA had asked Ocugen to pursue BLA submission and not Emergency Use Approval(EUA), paving the way for the vaccine's full approval in the United States.